Drug therapy for heart failure in older patients-what do they want?

Journal of Geriatric Cardiology

Volumn 12, Issue 2, 2015, Pages 165-173

  Zachariah, Donah ^a   Taylor, Jacqueline ^b   Rowell, Nigel ^c   Spooner, Clare ^d   Kalra, Paul R ^a  

^a PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c SOUTH TEES HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d Servier Laboratories Ltd   (United Kingdom)

Author keywords

Heart failure; Heart rate; Quality of life; The elderly

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; IVABRADINE; LISINOPRIL; LOSARTAN; METOPROLOL; NEBIVOLOL; PERINDOPRIL; PLACEBO; SPIRONOLACTONE; VALSARTAN;

AGED; BRADYCARDIA; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG TOLERABILITY; ELDERLY CARE; HEART FAILURE; HEART RATE; HUMAN; MORTALITY; QUALITY OF LIFE; REVIEW;

EID: 84925714688     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.11909/j.issn.1671-5411.2015.02.011     Document Type: Review

References (54)

1. National Heart Failure Audit UK, electronic version accessible from http://www.ucl.ac.uk/nicor/audits/heartfailure/additionalfiles/pdfs/annualreports/NHFA13medium.pdf.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
3. Gullestad L, Wikstrand J, Deedwania P, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the metoprolol controlled release/extended release randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2005;45:252-259
4. Cooney MT, Vartiainen E, Laatikainen T, et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 2010;159:612-619.
5. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: Prospective multinational observational study (GRACE). BMJ 2006;333:1079-1080.
6. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821.
7. Castagno D, Skali H, Takeuchi M, et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM Program. JAMA 2012;59:1785-1795.
8. Habal MV, Liu PP, Austin PC, et al. Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure; Circ Heart Fai. 2013 Dec. 2. DOI: 10.1161/CIRCHEARTFAILURE.113.000429.
9. Menown IB, Davies S, Gupta S, et al. Resting heart rate and outcomes in patients with cardiovascular disease: where do we currently stand? Cardiovasc Ther 2013;31:215-223.
10. Lang CC, Gupta S, Kalra P, et al. Elevated heart rate and cardiovascular outcomes in patients with coronary artery disease: Clinical evidence and pathophysiological mechanisms. Atherosclerosis 2010;212:1-8.
11. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
12. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
13. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
14. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007.
15. Flather MD, Shibata MC, Coats AJ, et al. Randomised trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225.
16. Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008;101:865-869.
17. Cullington D, Goode KM, Clark AL, et al. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail 2012;4:737-747.
18. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet 2010;376:875-885.
19. European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure2012: The task force for the diagnosis and treatment of acute and chronic heart failure2012 of the European Society of Cardiology. ESC Committee for practice guidelines. Eur J Heart Fail 2012;14:803-869.
20. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373.
21. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrolment criteria for clinical trials in heart failure. Am Heart J 2003;146:250-257.
22. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-907.
23. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study; Eur Heart J 2006;27:2338-2345.
24. Cohen-Solal A, McMurray JJ, Swedberg K, et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the candesartan in heart failureas-sess-ment of reduction in mortality and morbidity programme. Eur Heart J 2008;29:3022-3028..
25. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549.
26. Tavazzi L, Swedberg K, Komajda M, et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail. Published Online First: 2013 Jun. 26. DOI: 10.1093/eurjhf/hft102.
27. Abete P, Testa G, Della-Morte D, et al. Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev 2013;18:529-551.
28. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226-1233.
29. Cené CW, Loehr L, Lin FC, et al. Social isolation, vital exhaustion, and incident heart failure: findings from the Atherosclerosis Risk in Communities Study. Eur J Heart Fail. 2012;14:748-753.
30. Kim ES, Smith J, Kubzansky LD. Prospective study of the association between dispositional optimism and incident heart failure. Circ Heart Fail. 2014;7:394-400.
31. Bentley B, De Jong MJ, Moser DK, et al. Factors related to nonadherence to low sodium diet recommendations in heart failure patients. Eur J Cardiovasc Nurs 2005;4:331-336.
32. Le Corvoisier P, Bastuji-Garin S, Renaud B, et al. Functional status and co-morbidities are associated with in-hospital mortality among older patients with acute decompensated heart failure: a multicentre prospective cohort study. Age Ageing. 2015;44:225-231.
33. Lupón J, Gastelurrutia P, de Antonio M, et al. Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value. Eur J Heart Fail 2013;15:103-109.
34. Stevenson LW, Hellkamp AS, Leier CV, et al. Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol 2008;52:1702-1708.
35. Chang SW, Davidson PM, Newton PJ, et al. What is the methodological and reporting quality of health related quality of life in chronic heart failure clinical trials? Int J Cardiol 2013;164:133-140
36. Efficace F1, Bottomley A, Osoba D, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 2003;21:3502-3511.
37. Kalra PR, Morley C, Barnes S, et al. Discontinuation of betablockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2013;167:2695-2699.
38. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 2011;32:2395-2404.
39. Majani G, Giardini A, Opasich C, et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the valsartan heart failure trial. J Card Fail 2005;11:253-259.
40. Mansour S, Youssef A, Rayan M, et al. Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure. The Egyptian Heart Journal 2011;63:79-85
41. Sarullo FM, Fazio G, Puccio D, et al, Impact of "off-label" use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther 2010;15:349-355
42. Ni H, Toy W, Burgess D, et al. Comparative responsiveness of short-form 12 and minnesota living with heart failure questionnaire in patients with heart failure. J Card Fail 2000;6:83-91.
43. National Institute of Health and Clinical Excellence (NICE). NICE clinical guideline 108 chronic heart failure: management of chronic heart failure in adults in primary and secondary care. 2010
44. Ingle L, Shelton RJ, Rigby AS, et al. The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure. Eur Heart J 2005;26:1742-1751
45. Shah MR, Hasselblad V, Gheorghiade M, et al. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol 2001;88:987-993.
46. Rogers WJ, Johnstone DE, Yusuf S, et al. Quality of life among 5, 025 patients with left ventricular dysfunction randomized between placebo and enalapril: the studies of left ventricular dysfunction. J Am Coll Cardiol 1994;23:393-400.
47. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997;3:173-179.
48. Sanderson JE, Chan SKW, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522-1528.
49. Cowley AJ, Wiens BL, Segal R, et al. Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy. Qual Life Res 2000;9:377-384.
50. Fung JW, Chan SK, Yeung LY, et al. Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. Eur J Heart Fail 2002;4:489-494.
51. Lader E, Egan D, Hunsberger S, et al. The effect of digoxin on the quality of life in patients with heart failure. J Card Fail 2003;9:4-12.
52. Majani G, Giardini A, Opasich C, et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the valsartan heart failure trial. J Card Fail 2005;11:253-259.
53. Veazie PJ, Noyes K, Li Q, et al. Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J Am Coll Cardiol 2012;60:1940-1944.
54. Valentina Lazzarini, Robert J. Mentz, Mona Fiuzat, et al. Heart failure in elderly patients-distinctive features and unresolved issues. Eur J Heart Fail 2013;15:717-723.